Gilead Sciences/$GILD
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
17,600
ISIN
US3755581036
Website
Gilead Sciences Metrics
BasicAdvanced
$134B
22.83
$4.73
0.28
$3.10
2.93%
Price and volume
Market cap
$134B
Beta
0.28
52-week high
$119.96
52-week low
$64.86
Average daily volume
8.6M
Dividend rate
$3.10
Financial strength
Current ratio
1.369
Quick ratio
0.998
Long term debt to equity
131.104
Total debt to equity
131.104
Dividend payout ratio (TTM)
66.02%
Interest coverage (TTM)
11.01%
Profitability
EBITDA (TTM)
13,724
Gross margin (TTM)
78.29%
Net profit margin (TTM)
20.76%
Operating margin (TTM)
38.11%
Effective tax rate (TTM)
12.60%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
12.14%
Return on equity (TTM)
32.66%
Valuation
Price to earnings (TTM)
22.83
Price to revenue (TTM)
4.686
Price to book
7.05
Price to tangible book (TTM)
-15.81
Price to free cash flow (TTM)
13.678
Free cash flow yield (TTM)
7.31%
Free cash flow per share (TTM)
789.57%
Dividend yield (TTM)
2.87%
Forward dividend yield
2.93%
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
1,118.07%
3-year revenue growth (CAGR)
1.51%
10-year revenue growth (CAGR)
0.45%
3-year earnings per share growth (CAGR)
9.74%
10-year earnings per share growth (CAGR)
-5.99%
3-year dividend per share growth (CAGR)
2.72%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Bulls say / Bears say
Gilead Sciences reported a 6% increase in revenue to $7.57 billion in Q4 2024, surpassing Wall Street's projection of $7.14 billion, indicating strong financial performance. (reuters.com)
The company announced an additional $11 billion investment in U.S. manufacturing and research, bringing total planned investment to $32 billion through 2030, which could enhance domestic capabilities and drive growth. (reuters.com)
Gilead's HIV drug Biktarvy saw a 7% increase in sales to $3.15 billion in Q1 2025, reflecting strong demand and market presence. (reuters.com)
Gilead agreed to pay $202 million to settle a lawsuit accusing the company of providing kickbacks to doctors to promote its HIV drugs, which could impact its financials and reputation. (reuters.com)
The company reported a 5% drop in sales of its cancer drug Trodelvy to $293 million in Q1 2025, attributed to pricing and inventory issues, indicating potential challenges in its oncology segment. (reuters.com)
Gilead's cell therapy product sales declined by 3% amid rising competition, suggesting potential market share loss in this segment. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention
Business Wire·2 days ago
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead
Proactive Investors·2 days ago
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Business Wire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun27
Gilead Sciences
Dividend·Payment
$0.79Per share
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $134B as of June 20, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 22.83 as of June 20, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $3.1 and the yield is 2.93%. Gilead Sciences has a payout ratio of 66.02% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for June 27, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.